Robert Dzialo

Partner at Goodwin Procter

Robert Dzialo is a partner in the Technology group and Business Law department at Goodwin Procter LLP.1 He is a highly accomplished legal professional specializing in advising public and private companies, particularly in the technology, healthcare, and life science industries.1

Professional Experience

Robert primarily focuses on mergers and acquisitions (M&A) transactions, with extensive experience representing both strategic acquirers and acquisition targets.1 His expertise extends to various corporate matters, including:

Venture capital and growth equity financings
Public securities offerings
Corporate restructurings
Other strategic transactions

He joined Goodwin in 2014 and has since been involved in numerous high-profile deals.1

Notable Client Representations

Robert has represented several prominent clients in significant transactions, including:

Strategic Acquisitions::

PillPack in its sale to Amazon.com
Padlock Therapeutics in its $600 million sale to Bristol-Meyers Squibb
HubSpot in multiple acquisitions
PTC in its $1.5 billion acquisition of ServiceMax

Financial Acquisitions::

Monotype in its $825 million sale to private equity firm HGGC
Acquia in its sale to Vista Equity Partners

Private Financings::

Whoop in preferred equity financings totaling over $300 million
Generate Biomedicines in nearly $700 million of equity financings

Public Offerings::

Underwriters in Endurance International Group's follow-on public offerings
BridgeBio in its $372 million initial public offering

Education and Recognition

Robert holds a Juris Doctor (JD) from Boston College Law School, where he graduated in 2014 and served as a senior editor for the Boston College Law Review.1 He also earned a Bachelor of Arts (BA) from James Madison University in 2010.1

His exceptional work has been recognized by The Best Lawyers in America, where he was named in the "Ones to Watch" category for Corporate Law in 2021 and 2022.1